ANVS earnings analysis
What we found in ANVS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Annovis reported $0 revenue and diluted EPS of $(0.40), improving by $0.23 from $(0.63) in the prior quarter and exceeding the $(0.46) consensus estimate. Clinical execution was constructive, with full enrollment of the 850-patient Alzheimer’s Phase 3 trial and 266 Parkinson’s extension-study patients enrolled. However, the $14.8 million net loss and $18.7 million cash balance keep liquidity and financing risk elevated, and the 10-Q provides no numeric financial guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS improved and beat consensus
- Revenue remained $0, while diluted EPS improved to $(0.40) from $(0.63) in 2026Q1, a $0.23 sequential improvement, and beat the $(0.46) consensus estimate by $0.06.
- Alzheimer’s trial fully enrolled
- The pivotal Alzheimer’s Phase 3 trial reached full enrollment of 850 patients, supporting advancement of the company’s lead clinical program.
- Parkinson’s extension advanced
- The Parkinson’s open-label extension study reached 266 enrolled patients, indicating continued clinical-program execution.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No revenue and sizable net loss
- The company reported $0 revenue and a $14.8 million net loss for the quarter, underscoring its ongoing pre-commercial operating profile.
- Liquidity remains a key risk
- Cash was $18.7 million, leaving liquidity dependent on additional financing or expense management while clinical programs continue.
- Insider trading-plan terminations
- Two directors or officers terminated Rule 10b5-1 plans covering an aggregate 321,426 shares: 270,000 shares for CEO Maria Maccecchini and 51,426 shares for Director Mark White.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.4
What they said about what is next.
No numeric revenue or EPS guidance was provided in the 10-Q; the filing states that there were no material changes to the risk-factor disclosures from the 2025 Form 10-K.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- Annovis Bio reported a challenging Q1 2026, with a revenue of $0.0 and a diluted EPS loss of $0.63, falling short of the expected loss of $0.35. Operating expenses surged to $18 million, primarily driven by increased…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ANVS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever